575 filings
Page 5 of 29
6-K
t5336z6jqemy7xukr
16 Mar 21
Current report (foreign)
1:15pm
6-K
q15hje5 0dq
11 Mar 21
Announces the Initiation of Its Preclinical Program for the Potential
8:30am
6-K
ui812n7w rn
9 Mar 21
Current report (foreign)
7:00am
6-K
jo2lf3oknxj iyj
18 Feb 21
Current report (foreign)
4:05pm
6-K
e0je3
2 Feb 21
Current report (foreign)
7:40am
6-K
snk0 xouc39d7dfnembp
28 Jan 21
Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
4:05pm
6-K
fwww1wddjjuidvq
26 Jan 21
Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
5:30pm
6-K
2yxcrt8 8s6xagvux
7 Dec 20
Current report (foreign)
8:15am
6-K
0u1uupks 138eu0t1s
16 Nov 20
Current report (foreign)
8:15am
6-K
wwo18af n6g
5 Nov 20
Condensed Interim Consolidated Financial Statements
4:32pm
6-K
y4qn4b
7 Oct 20
Current report (foreign)
9:11am
6-K
t24uq
5 Aug 20
Condensed Interim Consolidated Financial Statements
9:02pm
6-K
906v06njdn3w 1k
5 Aug 20
Current report (foreign)
9:22am
6-K
k4uzghbqgi9u4ga7g5
4 Aug 20
Aeterna Zentaris Announces $7.0 Million Registered Direct Offering priced at-the-market
12:00am
6-K
gs0puw
31 Jul 20
Aeterna Zentaris Announces Continued Expansion of Intellectual Property Portfolio for Macimorelin with Additional Patent Applications
8:51am
6-K
t0cv1 vpn
31 Jul 20
Current report (foreign)
12:00am
6-K
r4v bw22e
29 Jul 20
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
7:10am
6-K
dpv6s dox78u2
6 Jul 20
AETERNA zentaris announces pricing of $12 mIllion public offering
7:00am
6-K
qxqvzybbbu5b kg8v
25 Jun 20
AETERNAzentaris ANNOUNCES DISTRIBUTION AGREEMENT
8:05am
6-K
eexsvms0gs6n9h7w74n9
8 Jun 20
Current report (foreign)
8:30am